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Abstract
Introduction: The transactivation response element DNA-binding protein 43 kDa (TDP-43) is a major component of
the ubiquitin-positive and tau-negative inclusions in frontotemporal lobar degeneration and sporadic amyotrophic
lateral sclerosis (ALS). TDP-43 may accumulate in cases of Alzheimer’s disease (AD), Lewy body disease (LBD), and
argyrophilic grain disease (AGD). However, few studies have focused on the incidence and extent of TDP-43
deposition in aging.
Results: We analyzed 286 consecutive autopsy brains neuropathologically. Of these, 136 brains with pathologically
minimal senile changes were designated as control elderly brains (78.5 ± 9.7 y). For comparison, we selected 29 AD, 11
LBD, and 11 AGD patients from this series of autopsy brains. Sections of the hippocampus, amygdala, medulla
oblongata, and lumbar spinal cord were immunostained with anti-phosphorylated TDP-43 antibody (PSer409/
410). TDP-43 immunoreactive structures were classified into four types: dystrophic neurites (DNs), neuronal or
glial cytoplasmic inclusions, and intranuclear inclusions. TDP-43 immunoreactive structures were observed in
55/136 control elderly (40.0 %), 21/29 AD (72.4 %), 8/11 LBD (72.7 %), and 6/11 AGD (54.5 %) brains. TDP-43
immunoreactive structures in control elderly brains were mostly DNs. These DNs were predominantly present
in the uncus of the anterior hippocampus over age 65. The frequency of cases with DNs in the amygdala of
control elderly brains was less than that of AD, LBD, and AGD brains. The mean age at death was significantly
higher in cases with TDP-43 immunoreactive structures than cases without them.
Conclusions: In conclusion, TDP-43 immunoreactive DNs may develop as a consequence of aging processes in
the human brain. In particular, the uncus of the anterior hippocampus is an area highly susceptible to TDP-43
accumulation over age 65.
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Introduction
The transactivation response element DNA-binding
protein 43 kDa (TDP-43) is a major component of the
ubiquitin-positive and tau-negative inclusions in fronto-
temporal lobar degeneration (FTLD-TDP) and sporadic
amyotrophic lateral sclerosis (ALS) [1–3]. However, the
cytopathology and distribution pattern of TDP-43
immunoreactive deposits generally differ between FTLD-
TDP and ALS [3, 4].
Previous studies have indicated that TDP-43 immuno-
reactive inclusion bodies can be detected in other neuro-
degenerative disorders as well, including Alzheimer’s
disease (AD) [5–9], Lewy body disease (LBD) [6, 8, 10],
and argyrophilic grain disease (AGD) [11]. Furthermore,
several studies have focused on TDP-43 deposition in
the absence of neurodegenerative disorders [10, 12–14].
One such study demonstrated that TDP-43 deposition
increased with age and did not occur in individuals
younger than 65 years [12]. Another study indicated that
the incidence of TDP-43 deposition in the amygdala and
hippocampus of cognitively normal elderly individuals
was 36 % [14]. These previous studies suggest that TDP-
43 deposition may be associated not only with specific
neurodegenerative disorders but also with aging and
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specific anatomical areas. To further analyze the func-
tional role of TDP-43, it will be important to understand
the anatomical distribution of TDP-43 immunoreactive
deposits in a large number of elderly individuals with
neuropathologically minimal changes. The aim of this
study was to clarify the incidence and distribution of
TDP-43 deposition in control elderly brains by immuno-
histochemical analysis of a series of autopsied individ-
uals. We also analyzed TDP-43 immunoreactive deposits
in individuals with AD, LBD, and AGD for comparison.
Materials and methods
Brain samples
Tissue samples were collected at the Tokyo Metropolitan
Geriatric Hospital, which provides community-based
medical service to the elderly population. From February
2008 to July 2012, we obtained the 286 consecutive
autopsy brains (165 men and 121 women) used for this
study. Patient ages ranged from 43 to 104 years (mean ±
SD, 82.0 ± 9.6 y). Clinical information was retrospectively
obtained from the medical chart. The Mini-Mental State
examination (MMSE) [15] was used for evaluation of cog-
nitive function, and the clinical dementia scale (CDR) [16]
was employed for the grading of cognitive decline as
previously reported [17]. The brain samples used in this
study were registered to the Brain Bank for Aging
Research (BBAR) with the deceased’s relatives’ informed
consent to carry out comprehensive research. The
BBAR is approved by the ethics committee of the
Tokyo Metropolitan Geriatric Hospital and Institute of
Gerontology.
Neuropathology and immunohistochemistry
The brains and spinal cords were examined according
to routine protocols used in our laboratory [18]. Briefly,
the cerebral and cerebellar hemispheres as well as the
brainstem were dissected in the midsagittal plane at the
time of autopsy. In each case, part of the brain was
stored at −80 °C for further biochemical and molecular
analyses. The brains and spinal cords were fixed in
20 % buffered formalin (WAKO, Osaka, Japan) for 7–
13 days. After fixation in formalin, the cerebral hemi-
spheres, brainstem, and cerebellum were dissected
along the coronal, axial, and sagittal planes, respect-
ively. Representative anatomical areas were embedded
in paraffin, and 6-μm-thick sections were obtained to
diagnose each case neuropathologically. Sections were
stained with hematoxylin and eosin (H&E) and the
Klüver-Barrera methods. Selected sections were further
examined with modified methenamine and Gallyas–Braak
silver staining for senile changes, Congo red for amyloid
deposition, and Elastica Masson trichrome stain for vascu-
lar changes. Selected sections were immunostained with a
Ventana BenchMark GX autostainer (Ventana Medical
Systems, Tucson, AZ, USA) and an I-View Universal DAB
Detection Kit (Roche, Basel, Switzerland) in accordance
with the manufacturer’s instructions. The antibodies
employed are shown in Table 1. Histologic sections were
observed under a research microscope (Eclipse 90i; Nikon,
Tokyo, Japan).
Case selection
The case selection procedure in this study is shown in
Fig. 1. First, of the 286 consecutive autopsy cases, we se-
lected cases that met all of the following conditions and
defined them as control elderly cases that have minimal
senile neuropathologic changes: Braak’s neurofibrillary
tangle (NFT) stage II or less, senile plaque (SP) stage
[19] A or less, AGD stage [17] II or less, and Lewy body
stage [20] II or less. For comparison, we selected cases
with AGD stage III as AGD and those with Lewy body
stage above III as LBD. We also defined AD according
to our brain bank definition (Braak NFT stage above IV
and Braak’s SP stage C) [21].
As to the cases with comorbid pathologies and other
neurological disorders, we also provided the results of
TDP-43 pathology. However, they were not used for
comparison with control elderly cases because they were
Table 1 Antibodies used for immunohistochemistry
Antibody Type Dilution Source
Pser409/410 m 1:10000 A gift from M. Hasegawa, Japan
(phosphorylated TDP-43)
anti-human amyloid β m 1:50 IBL, Maebashi, Gunma, Japan
(11–28) (12B2)
AT8 m 1:1000 Innogenetics, Ghent, Belgium
(phosphorylated tau)
Psyn64 m 1:10000 A gift from T. Iwatsubo, Japan
(phosphorylated α-synuclein)
ubiquitin r 1:1000 Dako, Glostrup, Denmark
m, mouse monoclonal; r, rabbit polyclonal
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limited in number: AD plus LBD (n = 6), AD plus AGD
(n = 3), AD plus progressive supranuclear palsy (PSP)
[22] (n = 1), AD plus hippocampal sclerosis (HS) (n = 1),
LBD plus AGD (n = 1), LBD plus PSP (n = 1), AGD plus
HS (n = 1), senile dementia with tangles (NFTD) (n = 6)
[23], Creutzfeldt–Jakob disease (CJD) (n = 4), ALS/ALS
with dementia (n = 4), multiple system atrophy (MSA)
(n = 3), spinocerebellar ataxia type 6 (SCA6) (n = 2),
spinocerebellar ataxia type 3 (SCA3) (n = 1), PSP (n = 2),
HS (n = 2), dentatorubral–pallidoluysian atrophy (DRPLA)
(n = 1), corticobasal degeneration (CBD) (n = 1), FTLD-
TDP (n = 1), and mitochondrial encephalopathy with
lactic acidosis and stroke-like episodes (MELAS) (n = 1).
Of the remaining cases, we identified the followings as
intermediate pathologies that did not fulfill diagnostic
criteria: Braak NFT stage above III and Braak’s SP stage A
as neurofibrillary tangle-predominant change (NFTC,
n = 27), Braak NFT stage above III and Braak’s SP stage
above B as AD type change (ADC, n = 18), and Braak
NFT stage II or less and Braak’s SP stage above B as
plaque dominant senile change (PSC, n = 12).
Evaluation of severity and distribution of TDP-43
immunoreactivity
The presence and severity of TDP-43 immunoreactive
structures were assessed in four brain sections including
the anterior hippocampus, amygdala, medulla oblongata,
and lumbar spinal cord. In fact, the anterior hippocam-
pus is key anatomical structures of FTLD-TDP. In
addition, TDP-43 immunoreactive deposits have been
well analyzed in AD, DLB and AGD in the limbic re-
gions [5, 6, 8–11]. The medulla oblongata and spinal
cord are important areas in association with ALS with
TDP-43 [4]. Therefore, we considered that those four
areas are appropriate for the study about TDP-43 path-
ology in control elderly brains. We assessed TDP-43
immunoreactive structures in each anatomical region
shown in Table 2 and Fig. 2 under a 10× objective. Each
anatomical region was identified using the neuroanat-
omy atlas [24]. The uncus was identified and analyzed at
the level of amygdala and anterior hippocampus [25].
Neuronal cytoplasmic inclusions (NCIs), glial cyto-
plasmic inclusions (GCIs), and neuronal intranuclear
inclusions (NIIs) immunoreactive for TDP-43 were
quantitatively analyzed and scored as 0 to 3 depending
on the total number of TDP-43 immunoreactive NCIs,
GCIs, or NIIs: 0, none; 1, 1–3; 2, 4–9; and 3, ≥10.
TDP-43 immunoreactive dystrophic neurites (DNs)
were semi-quantitatively scored as 0 to 3: 0, absent; 1,
sparse; 2, moderate; and 3, severe.
Statistical analysis
The Mann–Whitney U test was used to compare the age
at death and brain weight between TDP-43–positive and
TDP-43–negative groups. Fisher’s exact test was used to
compare the male-to-female ratio and number of TDP-
43 structures. A p value of less than 0.05 was considered
statistically significant.
Fig. 1 Case selection procedure. NFT, neurofibrillary tangle; SP,
senile plaque; AGD, argyrophilic grain disease; LB, Lewy body; AD,
Alzheimer’s disease; LBD, Lewy body disease (Parkinson’s disease
and dementia with Lewy bodies); PSP, progressive supranuclear
palsy; HS, hippocampal sclerosis; NFTD, NFT-predominant form of
senile dementia; CJD, Creutzfeldt–Jakob disease; ALS, amyotrophic
lateral sclerosis; MSA, multiple system atrophy; SCA, spinocerebellar
ataxia; DRPLA, dentatorubral-pallidoluysian atrophy; CBD, corticobasal
degeneration; FTLD, frontotemporal lobar degeneration; MELAS,
mitochondrial encephalopathy with lactic acidosis and stroke-like
episodes; NFTC, NFT-predominant change; ADC, AD-type change;
PSC, plaque dominant senile change
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Results
The demographics of the cases in this study are shown
in Table 3. We selected 136 cases as control elderly
(mean age at death ± 1 SD, 78.5 ± 9.7 y). For comparison,
we selected 29 AD, 11 LBD, and 11 AGD cases from
the series of autopsied individuals. Compared with
the control elderly group, the mean age at death was
higher for AD, LBD, and AGD groups (Table 3).
Distribution of TDP-43 pathology in control elderly brains
TDP-43 immunoreactive structures were found in
55/136 (40.0 %) cases (Table 4). Most of these struc-
tures were DNs (53/136 cases, 39.0 %; Table 5); they
were predominantly detected at the uncus of the an-
terior hippocampus (29/136 cases, 21.3 %; Table 5,
Fig. 3a). In rare instances, DNs were present in
other limbic areas such as the uncus of the amygdala
(5/134 cases, 3.7 %; two cases of amygdala were un-
available, Table 5). In control elderly brains, TDP-43
immunoreactive GCIs and NCIs were rare. In fact,
GCIs were observed only in a 94-year-old woman’s
entorhinal cortex and NCIs only in a 98-year-old
woman’s subiculum and pyramidal layer (Table 5).
No NIIs were present in control elderly brains. TDP-
43 immunoreactive DNs were also found in the inferior
olivary complex (14/136 cases, 10.3 %), anterior horn
(7/136 cases, 5.1 %), and white matter of the lumbar
spinal cord (11/136 cases, 8.1 %), as shown in Table 5.
No NCIs or GCIs were found in the medulla oblongata
or lumbar spinal cord.
Table 2 Brain regions analyzed in this study
area regions





Amygdala cortical amygdaloid nucleus as medial part
lateral part including basolateral, lateral
amygdaloid nucleus
uncus
Medulla oblongata dorsal motor nucleus of the vagus








white matter of spinal cord
central gray matter
Fig. 2 Evaluated anatomical regions in this study. a anterior hippocampus; b amygdala; c medulla oblongata; d lumbar spinal cord. Each
anatomical region was identified using the neuroanatomy atlas [24]. The uncus was defined and identified using the human hippocampus,
third edition [25]
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Distribution of TDP-43 pathology in AD, LBD,
and AGD brains
AD brains
TDP-43–positive structures were found in 21/29
(72.2 %) AD brains and were widely distributed in the
amygdala and hippocampus (Tables 4, 5). These struc-
tures were composed of NCIs (17/29 cases, 58.6 %)
and GCIs (18/29 cases, 62.1 %) as well as DNs (19/29
cases, 65.5 %) (Fig. 3b, c). DNs were observed in the
uncus of the anterior hippocampus (11/28 cases,
39.3 %; in one case, the anterior hippocampus was un-
available) as well as in the amygdala (14/29 cases,
48.3 %). In 7/29 cases (24.1 %), TDP-43 immunoreac-
tive NIIs were also present in the amygdala and hippo-
campus (Fig. 3d). To a lesser degree, TDP-43–positive
DNs were found in the medulla oblongata (5/29 cases;
17.2 %) and lumbar spinal cord (3/29 cases; 10.3 %).
There were neither NCIs nor GCIs in any case of AD
(Table 5).
LBD brains
TDP-43 immunoreactive structures were found in 8/11
(72.7 %) LBD brains and predominantly observed in the
uncus of the anterior hippocampus and amygdala
(Tables 4, 5). To a lesser degree, they were also found in
the amygdaloid nuclei, entorhinal cortex, subiculum, and
pyramidal cells of the hippocampus. TDP-43 immunore-
active structures mainly took the form of DNs (8/11
cases, 72.7 %), and occasionally of NCIs or GCIs in the
hippocampus and amygdala (2/11 cases, 18.2 %). DNs
were observed in the uncus of the anterior hippocampus
(5/11 cases, 45.5 %) and in the amygdala (3/11 cases,
27.3 %). TDP-43 immunoreactive NIIs were found in the
entorhinal cortex of only one case. In the medulla
oblongata, TDP-43 immunoreactive DNs were present
in the inferior olivary complex (4/11 cases, 36.4 %;
Table 5). There were no DNs in the spinal cord. No
NCIs or GCIs were found in any case of LBD.
AGD brains
TDP-43 immunoreactive structures were found in 6/11
(54.5 %) AGD brains and observed in the uncus and
amygdaloid nuclei (Tables 4, 5). These structures were
DNs (6/11 cases, 54.5 %). TDP-43 immunoreactive NCIs
or GCIs were also found in the amygdaloid nuclei (3/11
cases, 27.3 %). DNs were observed in the uncus of the
anterior hippocampus (5/11 cases, 45.5 %) and amygdala
(3/10 cases, 33.3 %; one case was unavailable). No TDP-
43–positive NIIs were found in these brains. In the me-
dulla oblongata, we found TDP-43 immunoreactive DNs
Table 3 Demographics of cases included in this study
Control elderly AD LBD AGD
Number (case) 136 29 11 11
Male, Female 95, 41 12, 17 9, 2 4, 7
Mean age at death 78.5 ± 9.7* 86.0 ± 6.2 84.0 ± 5.6 86.6 ± 6.3
(years, mean ± SD)
M ean brain weight 1257 ± 129 1168 ± 185 1208 ± 77.4 1159 ± 129
(grams, mean ± SD)
AD, Alzheimer’s disease; LBD, Lewy body disease; AGD, Argyrophilic grain disease; SD, standard deviation
*, p < 0.05 compared with AD, LBD and AGD
Table 4 Presence of TDP-43 pathology






























Male, Female 41, 14 54, 27 N.S. 9, 12 3, 5 N.S. 6, 2 3, 0 N.S. 2, 4 2, 3 N.S.
Mean age at death 80.6 ± 9.3 77.1 ± 9.7 0.038 86.2 ± 6.8 85.5 ± 4.5 N.S. 85.1 ± 4.6 81.0 ± 6.7 N.S. 90.3 ± 4.8 82.2 ± 4.7 0.028




















(grams, mean ± SD)
AD, Alzheimer’s disease; LBD, Lewy body disease; AGD, Argyrophilic grain disease; SD, standard deviation; N.S., not significant
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Table 5 TDP-43 distribution in this study
Control elderly AD LBD AGD
n = 136 n = 29 n = 11 n = 11
score score score score
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
Dentate gyrus DN 135 0 0 0 20 4 0 1 11 0 0 0 10 0 0 0
GCI 135 0 0 0 20 1 4 0 11 0 0 0 10 0 0 0
NCI 135 0 0 0 18 2 2 3 10 1 0 0 10 0 0 0
NII 135 0 0 0 22 3 0 0 11 0 0 0 10 0 0 0
Uncus (Hippocampus) DN 107 13 12 4 17 4 4 3 6 3 2 0 6 4 1 0
GCI 136 0 0 0 21 0 4 3 10 1 0 0 11 0 0 0
NCI 136 0 0 0 17 2 3 6 11 0 0 0 10 0 1 0
NII 136 0 0 0 27 1 0 0 11 0 0 0 11 0 0 0
Pyramidal layer DN 136 0 0 0 21 2 3 2 11 0 0 0 11 0 0 0
GCI 136 0 0 0 18 2 5 3 11 0 0 0 11 0 0 0
NCI 135 1 0 0 16 3 6 3 10 1 0 0 11 0 0 0
NII 136 0 0 0 27 1 0 0 11 0 0 0 11 0 0 0
Subiculum DN 133 2 1 0 19 5 2 2 9 1 1 0 11 0 0 0
GCI 136 0 0 0 16 4 3 5 11 0 0 0 11 0 0 0
NCI 135 1 0 0 15 3 5 5 11 0 0 0 11 0 0 0
NII 136 0 0 0 27 1 0 0 11 0 0 0 11 0 0 0
Entorhinal cortex DN 135 0 0 0 17 5 1 5 10 1 0 0 11 0 0 0
GCI 134 1 0 0 17 2 4 5 10 0 1 0 11 0 0 0
NCI 135 0 0 0 19 2 3 4 10 0 1 0 11 0 0 0
NII 135 0 0 0 24 4 0 0 10 1 0 0 11 0 0 0
Amygdala Medial part DN 130 4 0 0 18 4 4 3 10 1 0 0 9 0 1 0
GCI 134 0 0 0 17 3 7 2 10 0 1 0 10 0 0 0
NCI 134 0 0 0 18 2 3 6 10 0 1 0 9 1 0 0
NII 134 0 0 0 28 1 0 0 11 0 0 0 10 0 0 0
Amygdala Lateral part DN 133 0 0 1 19 7 0 3 10 1 0 0 9 0 1 0
GCI 134 0 0 0 18 4 5 2 10 0 1 0 9 0 1 0
NCI 134 0 0 0 18 0 5 6 10 0 1 0 9 0 1 0
NII 134 0 0 0 28 1 0 0 11 0 0 0 10 0 0 0
Uncus (Amygdala) DN 129 3 2 0 15 8 3 3 8 3 0 0 7 2 1 0
GCI 134 0 0 0 16 6 7 0 9 2 0 0 10 0 0 0
NCI 134 0 0 0 16 6 3 4 10 1 0 0 9 1 0 0
NII 134 0 0 0 29 0 0 0 11 0 0 0 10 0 0 0
Dorsal motor nucleus of the vagus DN 136 0 0 0 27 2 0 0 11 0 0 0 11 0 0 0
GCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NII 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
Nucleus of hypoglossal nerve DN 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
GCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NII 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
Inferior olivary complex DN 122 11 3 0 25 2 2 0 7 4 0 0 9 2 0 0
GCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
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in the inferior olivary complex in two cases (2/11 cases,
18.2 %; Table 5). In the lumbar spinal cord, we found
TDP-43 immunoreactive DNs in the white matter in an
85-year-old male. Neither NCIs nor GCIs were found in
any of the AGD brains.
Age and frequencies of DNs in four groups
The mean age at death was significantly higher in cases
with TDP-43 immunoreactive structures than in those
without TDP-43 immunoreactive structures in control
elderly and AGD (Table 4). However, there were no sig-
nificant differences in the mean age at death in AD and
LBD (Table 4). Neither the brain weight nor sex ratio
differed significantly among the four groups.
Because DNs were the predominant form of TDP-43
immunoreactive structure and observed mostly in the
uncus in control elderly, we analyzed the frequencies of
DNs in the uncus of the anterior hippocampus and
amygdala in comparison with those of AD, LBD, and
AGD. There were no significant differences in the
frequency of cases with DNs in the uncus of the anter-
ior hippocampus between control elderly and disease
controls (Fig. 4a). In contrast, the frequency of cases
with DNs observed in the uncus of the amygdala was
higher in AD, LBD, and AGD compared with control
elderly (Fig. 4b).
In addition, we focused on the association between
the percentage of cases carrying DNs in the uncus of
the anterior hippocampus and aging in control elderly.
DNs were observed from age 65 to 94. In these individ-
uals, there was no statistical association between the
rate of DNs and aging (Fig. 5). However, the rate of
DNs may increase beyond 90 years of age (Fig. 5).
The relationship between TDP-43 immunoreactivity
and cognitive function, cerebrovascular disease in control
elderly brains
In control elderly brains, the rates of cases with cogni-
tive impairment (CDR ≥ 0.5) among cases with and
without TDP-43 immunoreactive structures were
38.3 % (18/47 cases, CDR was unavailable in 8 cases)
and 34.3 % (28/70 cases, CDR was unavailable in 11
cases), respectively.
Table 5 TDP-43 distribution in this study (Continued)
NCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NII 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
Reticular formation DN 132 2 2 0 28 1 0 0 11 0 0 0 11 0 0 0
GCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NII 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
Pyramids DN 135 1 0 0 29 0 0 0 11 0 0 0 11 0 0 0
GCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NII 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
Anterior horn DN 129 7 0 0 28 1 0 0 11 0 0 0 11 0 0 0
GCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NII 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
Posterior horn DN 134 2 0 0 29 0 0 0 11 0 0 0 11 0 0 0
GCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NCI 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NII 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
White matter DN 125 11 0 0 27 2 0 0 11 0 0 0 10 1 0 0
Central gray matter DN 133 3 0 0 29 0 0 0 11 0 0 0 11 0 0 0
GC 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NC 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
NN 136 0 0 0 29 0 0 0 11 0 0 0 11 0 0 0
AD, Alzheimer’s disease; LBD, Lewy body disease; AGD, Argyrophilic grain disease; GCI, glial cytoplasmic inclusion; NCI, neuronal cytoplasmic inclusion; NII,
neuronal intranuclear inclusion. The dentate gyrus was unavailable in one case of control elderly, 3 cases of AD, and one case of AGD. The amygdala was
unavailable in two cases of control elderly and one case of AGD. The entorhinal cortex was unavailable in one case of control elderly. The anterior hippocampus
was unavailable in one case of AD
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In addition, we examined the influence of cerebrovas-
cular pathology. The rates of cases with cerebrovascular
pathology among cases with and without TDP-43 immu-
noreactive structures were 61.2 % (34/55 cases) and
67.9 % (55/81 cases), respectively. There were no signifi-
cant differences between cases with and without TDP-43
immunoreacrive structures.
TDP-43 pathology in comorbid pathologies, other
neurological disorders and intermediate pathologies.
TDP-43 immunoreactive structures were also found in
the following cases: AD plus LBD (5/6 cases, 83.3 %);
AD plus AGD (3/3 cases, 100 %); AD plus PSP (1/1 case,
100 %); AD plus HS (1/1 case, 100 %); LBD plus AGD
(1/1 case, 100 %); LBD plus PSP (0/1 case, 0 %); AGD
plus HS (1/1 case, 100 %); NFTD (3/6 cases, 50 %); CJD
(0/4 cases, 0 %); ALS/ALS with dementia (4/4 cases,
100 %); MSA (2/3 cases, 66.7 %); SCA6 (2/2 cases,
100 %); SCA3 (0/1 case, 0 %); PSP (2/2 cases, 100 %);
HS (2/2 cases, 100 %); DRPLA (0/1 case, 0 %); CBD (1/1
case, 100 %); FTLD-TDP (1/1 case, 100 %); MELAS (0/1
case, 0 %); NFTC (13/27 cases, 48.1 %); ADC (9/18
cases, 50 %); and PSC (6/12 cases, 50 %).
Discussion
Our study is the first neuropathologic analysis that has
clarified the anatomical distribution of TDP-43 immuno-
reactive structures in elderly brains with minimal senile
neuropathologic changes in large numbers. We revealed
the following findings. First, TDP-43 immunoreactive
structures were present in 40 % of control elderly. Sec-
ond, these structures were predominantly observed at
the uncus of the anterior hippocampus as DNs over age
65. Third, the number of cases with DNs in the amyg-
dala of control elderly was less than that of AD, LBD, or
AGD. Fourth, no NCIs or GCIs were found in the me-
dulla oblongata and lumbar spinal cord in all four
groups. Finally, the mean age at death was significantly
higher in cases with TDP-43 immunoreactive structures
than those without such structures.
A few studies have assessed the frequency of TDP-43
immunoreactive structures in normal brain. Wilson et
al. reported that 2/63 (3 %) were positive for TDP-43 in
neurologically normal individuals ranging from 23 to
94 years old at death [13]. Another study of 110 cogni-
tively normal elderly brains (mean age at death 86 ± 6.0)
revealed that 40 cases (36.4 %) showed TDP-43 immu-
noreactivity in the limbic area [14]. In yet another study,
12 of 60 brains (20 %) without severe mental illness
(mean age; 68) were reported as TDP-43 immunoposi-
tive in the amygdala or hippocampus [12]. The wide
variation in the rate of TDP-43 immunoreactivity may
depend on the age distribution of the sample population
and the definition of a normal brain. In fact, the defin-
ition of a normal brain was based on the clinical infor-
mation in previous studies. Because we defined the
Fig. 3 TDP-43 immunoreactive structures in representative cases. a Dystrophic neurites in the uncus of the anterior hippocampus in the control
elderly brain. b Neuronal cytoplasmic inclusions (arrows) in the dentate gyrus in Alzheimer’s disease (AD). c Glial cytoplasmic inclusions (arrows) in
the entorhinal cortex in AD. d Neuronal intranuclear inclusion (arrow) in the dentate gyrus in AD. Scale bar = 20 μm
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control elderly brain by using a neuropathologic staging
system in association with neurodegenerative disorders
and aging, the present study could control the effects of
other protein deposits, including tau and α-synuclein, on
TDP-43.
The distribution of TDP-43 immunoreactive struc-
tures in control elderly was different from those in AD.
The structures in AD were widely present in the amyg-
dala and hippocampus. Furthermore, in most cases, the
TDP-43 immunoreactive structures in AD took the
form of NCIs/GCIs, whereas only two cases of control
elderly had GCIs or NCIs. These findings suggest that
the pathological mechanism of TDP-43 accumulation
in control elderly is different from that in AD. Al-
though the amygdala was considered to be the first af-
fected region of TDP-43 deposition in AD [26], TDP-43
immunoreactive structures in the amygdala may be
non-specific. In this study, the frequency of cases with
TDP-43 immunoreactive DNs observed in the uncus of
the amygdala was significantly higher in AD than that
in control elderly. This finding confirms that the se-
quential TDP-43 progression begins in the amygdala in
AD. Interestingly, two control elderly cases over 90
showed NCIs or GCIs in the hippocampus and para-
hippocampus. Therefore, a portion of the TDP-43 im-
munoreactive NCIs and GCIs may be associated with
aging. In addition, there is a possibility that these
cases had neurodegenerative disorders at the earliest
stages. Further cases need to be investigated to con-
firm these possibilities.
Previous studies that used a small number of cases
also reported that TDP-43 immunoreactive structures
were frequently observed in the amygdala in AD, LBD,
and AGD [5, 6, 8–11]. In the present study, TDP-43 im-
munoreactive DNs in the amygdala of control elderly
brains were less numerous than in that of AD, LBD or
AGD brains. Therefore, TDP-43 immunoreactive de-
posits in the amygdala are associated with deposits of
Fig. 5 Correlation between age and incidence of TDP-43 immunore-
active structures in the uncus of the anterior hippocampus in control
elderly brains. The incidence of TDP-43 positive brains ranged between
13 % and 27 % between ages 65 and 89 years. Although there were no
significant differences, the incidence of TDP-43–positive brains increased
to 50 % at ages 90 to 94 years
Fig. 4 Incidence of TDP-43 immunoreactive dystrophic neurites (DNs) in the uncus of the anterior hippocampus and amygdala. a There were no
significant differences in the number of cases with DNs in the uncus of the anterior hippocampus between control elderly brains and brains with
Alzheimer’s disease (AD), Lewy body disease (LBD), and argyrophilic grain disease (AGD). b The incidence of DNs in the amygdala was significantly
higher in the AD, LBD, and AGD brains than in control elderly brains
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proteins such as tau and α-synuclein, which are related
to other neurodegenerative disorders. In contrast, the
number of cases with TDP-43 immunoreactive DNs in
the uncus of the anterior hippocampus of control elderly
showed no significant differences compared with AD,
LBD, and AGD. Importantly, these DNs were present
from age 65 to 94 years in our study. In particular, the
proportion of TDP-43–positive cases was 13 % to 27 %
in the age range of 65–89 years and 50 % in the age
range of 90–94 years (Fig. 5). These findings suggest that
TDP-43 accumulation in the uncus of the anterior
hippocampus in the form of DNs is predominantly asso-
ciated with physiological aging and not with neurode-
generative disorders.
We found TDP-43 immunoreactive DNs in the me-
dulla oblongata and the spinal cord in control elderly
brains and there were no NCIs or GCIs in all groups.
These structures were predominantly located in the in-
ferior olivary nuclei and the white matter of the spinal
cord. The cases of AD, LBD, and AGD brains also
showed TDP-43 immunoreactive DNs in those anatom-
ical regions. We believe that the TDP-43 immunoreac-
tive DNs in those specific anatomical regions may be
associated with human physiological aging. In fact, the
distribution pattern of TDP-43 deposits in this study
clearly differs from that in ALS and FTLD-TDP brains
that show many NCIs [4, 27].
Our study has some limitations. Because many aging
brains have comorbid pathologies, the numbers of pure
AD, LBD, and AGD brains in this study were relatively
small. In addition, a part of TDP-43 accumulation of in
AD, LBD, and AGD brains may be influenced by the
aging process. In fact, for AD, LBD, and AGD, the mean
age of death was significantly higher than that for con-
trol elderly.
Although TDP-43 has been associated with memory
loss and medial temporal atrophy in AD [28], the role of
TDP-43 accumulation in control elderly brains remains
unresolved. The present study, we could not find the re-
lationship between cognitive function and TDP-43 path-
ology in control elderly cases. Since the present study
has not focused on neuropsychological examination, fur-
ther studies in large numbers are needed to determine
whether TDP-43 pathology might lead to subtle changes
in cognitive function.
Conclusions
In summary, our study clearly revealed that TDP-43 im-
munoreactive structures may develop as a consequence
of aging processes in the human brain. Most of them
were DNs not NCIs and GCIs, and were observed in the
uncus of anterior hippocampus. Additional studies may
be important to understand the role of TDP-43 accumu-
lation in normal human aging. Besides those control
elderly cases, we believe that the cases without TDP-43
immunoreactive deposits are also substantial for analysis
of pathomechanism of TDP-43 accumulation.
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